Empower Clinic Services, LLC. (d/b/a Empower Pharmacy) vs Eli Lilly & Co.

Ex. 2001 - Asami (WO 2014-192284A1)

Ex. 2002 - Eli Lilly Press Release (5.13.2022)

Ex. 2003 - PhRMA Research Development Policy Framework (Sept. 2024)

Ex. 2004 - Beauroyre (Abacum 6.25.2025)

Ex. 2005 - CCRPS, Phase III Clinical Trials Definitive Guide & Case Studies (6.8.2025)

Ex. 2007 - Johns Hopkins-Bloomberg Sch Pub Health (9.24.2018)

x. 2009 - NIH-clinicaltrials.gov, Eli Lilly, A Study of Tirzepatide (6.26.2017)

Ex. 2010 - Coskun et al. (Molecular Metabolism 2018)

Ex. 2011 - Eli Lilly Q2 2016 Earnings Presentation

Ex. 2012 - Eli Lilly & Co Q3 2017 Earnings Call Transcript (10.24.2017)

Ex. 2013 - Eli Lilly Press Release (10.4.2018)

Ex. 2014 - Frias et al. (Lancet 2018)

Ex. 2015 - Pharmaceutical Technology (10.5.2018)

Ex. 2006 - Fierce Healthcare (9.23.2011)

Ex. 2016 - Helfand (Fierce Pharma 10.8.2018)

Ex. 2017 - Eli Lilly Press Release (12.9.2020)

Ex. 2018 - Eli Lilly Press Release (2.17.2021)

Ex. 2019 - Eli Lilly Press Release (6.25.2021)

Ex. 2020 - Eli Lilly Press Release (6.21.2024)

Ex. 2021 - Frias et al. (NEJM 2021)

Ex. 2022 - Ludvik et al. (Lancet 2021)

Ex. 2023 - Jastreboff et al. (NEJM 2022)

Ex. 2025 - Kolata (NY Times 4.28.2022)

Ex. 2026 - Zoler (Medscape June 2022)

Ex. 2027 - Rosenstock (Diabetes Care 2023)

Ex. 2028 - Hosie (Business Insider 6.6.2022)

Ex. 2029 - Chavda et al. (Molecules 2022)

Ex. 2030 - Loftus (WSJ 4.3.2023)

Ex. 2031 - Drug Discovery Development (6.3.2021)

Ex. 2032 - Buntz (Drug, Discovery Dev. 4.28.2022)

Ex. 2033 - Mullard (Nature Revs. Drug Discovery 5.20.2022)

Ex. 2034 - Biochem PEG (5.20.2022)

Ex. 2035 - Wang (Drug Design Dev. Therapy 2022)

Ex. 2036 - Sainz (diaTribe Learn 9.21.2022)

Ex. 2037 - Doctors Business Network (4.28.2025)

Ex. 2038 - Buntz (Drug Discovery Dev. 10.16.2023)

Ex. 2041 - Zacks Equity Rsch. (Nasdaq 12.10.2020)

Ex. 2042 - Eli Lilly Press Release (11.8.2023)

Ex. 2043 - Eli Lilly Press Release (12.20.2024)

Ex. 2044 - FDA, Orange Book-Approved Drug Products With Therapeutic Equivalence Evaluations, Tirzepatide

Ex. 2045 - PubChem, Substance Record 910463-68-2

x. 2046 - Sun et al. (Acta Pharmaceutica Sinica B 2022)

Ex. 2047 - BIO et al., Clinical Development Success Rates & Contributing Factors 2011–2020 (Feb. 2021)

Ex. 2048 - Dowden & Munro (Nature Revs. Drug Discovery 2019)

Ex. 2049 - Eli Lilly - Tirzepatide Clinical Studies Listing (Clinicaltrials.gov)

Ex. 2050 - Eli Lilly - Tirzepatide Non-NCT Clinical Trials (compilation)

Ex. 2024 - Wadden et al. (Nature Med. 2023 )

Patent Owner's Brief on Discretionary Denial

Notice: Notice filing date accorded

Notice: Power of Attorney

Notice: Mandatory Notice

US Patent No. 9,474,780

Prosecution History of U.S. Patent No. 9,474,780

WO 2016111,971 International Search Report

WO 2016111,971 Written Opinion

WO 2011/119,657 A1 Publication

WO 2013/164,483 A1 Publication

WO 2006/097,537 A2 Publication

WO 2014/202,727 A1 Publication

Fields G. B. Introduction to peptide synthesis. Current protocols in protei

US 2015/0299281 A1 Publication

SAXENDA (liraglutide) injection drug label (Dec. 2014) (“SAXENDA”)

Nelson, D. L., et al., Chapters 4-5, 7, Lehninger Principles of Bio Part 1

Nelson, D. L., et al., Chapters 4-5, 7, Lehninger Principles of Bio Part 2

Segaloff, D. L., et al., Chapter 9: Internalization of Peptide Hormones and

Zhang Y., Baranov P.V., Atkins J.F., Gladyshev V.N. Pyrrolysine and selenoc

Merrifield R. B. Solid phase peptide synthesis. I. The synthesis of a tetra

Sawyer, W. H., Manning, M. Synthetic analogs of oxytocin and the vasopressi

Karten M.J., Rivier J.E. Gonadotropin-releasing hormone analog design. Stru

Garay R.P., El-Gewely R., Armstrong J.K, Garratty G., Richette P. Antibodie

Knudsen L.B. Liraglutide: the therapeutic promise from animal models. Int J

Ward B.P., et al. Peptide lipidation stabilizes structure to enhance biolog

Zhang L., Bulaj G. Converting peptides into drug leads by lipidation. Curr

Krauson A.J., He J., Wimley A.W., Hoffmann A.R., Wimley W.C. Synthetic mole

Lam K.S., et al. A new type of synthetic peptide library for identifying li

Liu T., Qian Z., Xiao Q., Pei D. High-throughput screening of one-bead-one-

Tautermann C.S. GPCR structures in drug design, emerging opportunities with

Donnelly D. The structure and function of the glucagon-like peptide-1 recep

Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. Teaching old receptors new

Yu Z, Jin T. New insights into the role of cAMP in the production and funct

Roed S.N., et al. Functional consequences of glucagon-like peptide-1 recept

Jorgensen R., Norklit Roed S., Heding A., Elling C. E. Beta-arrestin-2 as a

Jorgensen R., Kubale V., Vrecl M., Schwartz T.W., Elling C.E. Oxyntomodulin

Sonoda N, et al. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling

Siu F.Y., et al. Structure of the human glucagon class B G-protein-coupled

Hoare S.R. Mechanisms of peptide and nonpeptide ligand binding to Class B G

Hoare S. R. Allosteric modulators of class B G-protein-coupled receptors. C

Seino Y., Fukushima M., Yabe D. GIP and GLP-1, the two incretin hormones: S

Brown J.C., Mutt V., Pederson R.A. Further purification of a polypeptide de

Inagaki, N., et al. Gastric inhibitory polypeptide: Structure and chromosom

Dupre J., et al. Stimulation of insulin secretion by gastric inhibitory pol

Adrian T.E., Bloom S.R., Hermansen K., et al. Pancreatic polypeptide, gluca

Lund P.K., Goodman R.H., Dee P.C., Habener J.F. Pancreatic preproglucagon c

Hui H., Farilla L., Merkel P., Perfetti R. The short half-life of glucagon-

Singh A. K. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.

Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose‐depende

Montrose-Rafizadeh C., et al. High potency antagonists of the pancreatic gl

VICTOZA (liraglutide) injection drug label (Jan. 2010) (“VICTOZA”)

Bode B. Liraglutide: a review of the first once-daily GLP-1 receptor agonis

Neumiller J.J., Campbell R.K. Liraglutide: a once-daily incretin mimetic fo

BYDUREON (exenatide) injection drug label (Jan. 2012) (“BYDUREON”)

BYETTA (exenatide) injection drug label (Apr. 2005) (“BYETTA”)

TRULICITY (dulaglutide) injection drug label (Sept. 2014) (“TRULICITY”).

ADLYXIN (lixisenatide) injection drug label (Jul. 2016) (“ADLYXIN”)

OZEMPIC (semaglutide) injection drug label (Dec. 2017) (“OZEMPIC”)

Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects

Day J.W., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in

Pocai A., et al. Glucagon-like peptide 1/glucagon receptor dual agonism rev

Finan B., Ma T., et al. Unimolecular dual incretins maximize metabolic bene

Stenkamp R.E., et al. Crystal structure of rhodopsin: A G protein-coupled r

Rasmussen S.G., et al. Crystal structure of the human beta2 adrenergic G-pr

Stevens R. C., et al. The GPCR Network: a large-scale collaboration to dete

Berman, H. M., et al. The Protein Data Bank. Nuc Acids Res, 2000; 28(1), 23

Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler M

Adelhorst K., Hedegaard B.B., Knudsen L.B., Kirk O. Structure-activity stud

Manandhar B., Ahn J.M. Glucagon-like peptide-1 (GLP-1) analogs: recent adva

Thum A., Hupe-Sodmann K., et al. Endoproteolysis by isolated membrane pepti

Fineman M. S., et al., Clinical relevance of anti-exenatide antibodies: saf

Buse J. B., et al., Liraglutide Treatment Is Associated with a Low Frequenc

Doyle M.E., et al. The importance of the nine-amino acid C-terminal sequenc

Simonsen L., Holst J.J., Madsen, K., Deacon C.F. The C-terminal extension o

Tatarkiewicz, K., et al., A novel long-acting glucose-dependent insulinotro

WO 2015/067,715 A2 Publication

Keen, H. et al. Human insulin produced by recombinant DNA technology: safet

Curriculum Vitae of Dr. Virginia W. Cornish, Ph.D.

Declaration of Dr. Virginia W. Cornish, Ph.D.

Notice: Power of Attorney

Petition: as filed